Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 6/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411106 | 0.88 | ABL1 (0.50) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| Carbamic Acid SCHEMBL2847023 | 0.88 | ABL1 (0.48) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL8002727 | 0.83 | ABL1 (0.47) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL4644412 | 0.82 | HRH4 (0.49) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL4645149 | 0.79 | HTR7 (0.54) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL4686041 | 0.79 | HTR7 (0.54) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL15357779 | 0.79 | FLT3 (0.41) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL91488 | 0.79 | HRH4 (0.50) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL12411116 | 0.79 | HRH4 (0.46) | ABL1LCKCSF1RPDGFRBMAP2K2 | |
| SCHEMBL14110210 | 0.78 | MAPK1 (0.71) | ABL1LCKCSF1RPDGFRBMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7820687-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7579466-B2 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1996559-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007101165-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016345-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | ABL1 3418/4885LCK 1399/4885CSF1R 337/4885 |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ABL1 1009/4885LCK 1228/4885CSF1R 983/4885 |
| US-20080058357-A1 | PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, CD4 | ABL1 3418/4885LCK 1399/4885CSF1R 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.